MEGESTROL ACETATE IMPURITY B
Mismatch Repair Deficiency
Peking University People's HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
19 Active assets in the Mismatch Repair Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab 7 Hills Pharma, LLC | Phase 2 | B |
Pembrolizumab Jennifer Leddon | Phase 2 | B |
Cyclophosphamide Jennifer Leddon | Phase 2 | B |
Atezolizumab ImmunityBio, Inc. | Phase 2 | CCC |
Durvalumab ImmunityBio, Inc. | Phase 2 | CCC |
View all 25 →
Same molecule, other indications
MEGESTROL ACETATE IMPURITY B is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →